What is the appropriate treatment for paracetamol (acetaminophen) poisoning?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 1, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Treatment of Paracetamol Poisoning

Administer N-acetylcysteine (NAC) immediately to all patients with paracetamol poisoning who are at risk for hepatotoxicity, ideally within 8-10 hours of ingestion, as this dramatically reduces severe hepatotoxicity and mortality. 1

Risk Stratification and Treatment Algorithm

For Acute Ingestions (within 24 hours, known time)

Use the Rumack-Matthew nomogram to determine treatment need:

  • Measure serum paracetamol concentration between 4-24 hours post-ingestion
  • Plot the level on the nomogram (the FDA-modified version includes a "possible risk" zone 25% below the original "probable risk" line)

Treatment decisions based on nomogram:

  • Possible or Probable Risk Zone: Administer NAC immediately 1
  • Below the treatment line (No Risk): Do NOT administer NAC 1
  • Above the nomogram: Only 1 of 297 patients with no risk developed severe hepatotoxicity without treatment 1

Timing is Critical

The efficacy of NAC is time-dependent:

  • <8 hours: No severe hepatotoxicity when treated 1
  • 8-10 hours: 6.1% severe hepatotoxicity rate 1
  • >10 hours: 26.4% severe hepatotoxicity rate 1
  • 10-16 hours: 29% severe hepatotoxicity 1
  • 16-24 hours: 62% severe hepatotoxicity 1

Critical pitfall: Even delays beyond 10 hours still provide benefit—NAC reduces morbidity and mortality even when started 12-24 hours post-ingestion 1

Special Populations Requiring Different Approach

When the Nomogram CANNOT Be Used

Administer NAC empirically in these situations 1:

  1. Unknown or unreliable ingestion time
  2. Presentation >24 hours post-ingestion
  3. Extended-release formulations (≥10g or ≥200 mg/kg)
  4. Repeated supratherapeutic ingestions (multiple doses over time)
  5. Detectable paracetamol level with unknown history

Patients with Existing Liver Injury

Level B Recommendation: Administer NAC to patients with hepatic failure thought to be due to paracetamol, regardless of time since ingestion 1

  • NAC reduces mortality by 28% (from 80% to 52%) in fulminant hepatic failure 1
  • Decreases cerebral edema and need for inotropic support 1

Level C Recommendation: Administer NAC to patients with hepatotoxicity (elevated transaminases) and suspected paracetamol overdose, even without hepatic failure 1

NAC Dosing Regimens

The most recent evidence supports a modified two-bag regimen over the traditional three-bag protocol 2:

  • Loading dose: 200 mg/kg over 4 hours
  • Maintenance: 100 mg/kg over 16 hours
  • Advantage: Significantly fewer adverse reactions with similar efficacy 2

High-Risk/Massive Ingestions

For paracetamol concentrations more than double the nomogram line 2:

  • Increase acetylcysteine dosing
  • Consider ingestions ≥30g or ≥500 mg/kg as requiring increased NAC doses

Adjunctive Measures

Gastrointestinal Decontamination

Activated charcoal is the preferred decontamination method if the patient presents within 4 hours of ingestion 3:

  • More effective than gastric lavage or ipecacuanha
  • Best risk:benefit ratio among decontamination options
  • Reduces paracetamol absorption

Do NOT use gastric lavage or ipecacuanha as first-line—activated charcoal is superior 3

Monitoring Parameters

Serial monitoring is essential 4:

  • Liver function tests (AST, ALT) at presentation and serially
  • PT/INR to assess synthetic liver function
  • Serum bilirubin
  • Renal function (paracetamol can cause acute kidney injury)

Important caveat: Normal transaminases in the ED do not exclude risk of developing toxicity over the next several hours 1

What Does NOT Work

Insufficient evidence for these interventions 5:

  • Cimetidine: No proven benefit in comparative trials
  • Fomepizole: Case reports inconclusive, no comparative trials
  • Charcoal hemoperfusion: No demonstrated benefit, one death in treatment group 3

Key Clinical Pitfalls to Avoid

  1. Waiting for symptoms: Patients are often asymptomatic early—treat based on history and levels, not symptoms
  2. Dismissing "low-risk" repeated ingestions: Repeated supratherapeutic dosing can cause toxicity even with therapeutic intent
  3. Delaying NAC for confirmatory testing: Start NAC empirically if history suggests risk while awaiting levels
  4. Stopping NAC prematurely: Complete the full course even if patient feels well
  5. Missing extended-release formulations: These require full NAC course regardless of initial levels (≥10g or ≥200 mg/kg) 2
  6. Ignoring psychiatric evaluation: Most intentional overdoses require mental health assessment before discharge 4

Bottom Line Treatment Approach

Start NAC immediately if:

  • Acute ingestion ≥200 mg/kg or 10g (whichever is less) 6
  • Paracetamol level plots in possible/probable risk zone on nomogram
  • Any detectable level with unknown/unreliable history
  • Elevated transaminases with suspected paracetamol exposure
  • Hepatic failure attributed to paracetamol

The evidence overwhelmingly supports early NAC administration as the single most important intervention to prevent morbidity and mortality from paracetamol poisoning 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.